Next 10 |
Pulmatrix Announces Cross License Agreement and Transfer of Laboratory to MannKind Corporation PR Newswire Cross license involves Pulmatrix iSPERSE™ technology and MannKind's Cricket ® inhalation device. Pulmatrix transferring leased building,...
Immediate opportunity to increase capacity for formulation and early asset development in upgraded Boston area R&D space Non-cash deal includes royalty-free iSPERSE ™ technology license in exchange for access to MannKind’s Cricket ® inhaler ...
2024-05-15 01:22:49 ET Summary MannKind's Q1 revenue rose 63% year-over-year; net income was $10.63 million, reversing a prior loss. Tyvaso DPI, utilizing MannKind’s technosphere technology, continues to capture significant PAH market interest. Despite high current asse...
2024-05-09 00:15:12 ET Image source: The Motley Fool. MannKind (NASDAQ: MNKD) Q1 2024 Earnings Call May 08, 2024 , 5:00 p.m. ET Operator Continue reading For further details see: MannKind (MNKD) Q1 2024 Earnings Call Transcript
2024-05-08 20:55:25 ET MannKind Corporation (MNKD) Q1 2024 Earnings Conference Call May 8, 2024 5:00 PM ET Company Participants Michael Castagna - Chief Executive Officer Steve Binder - Executive Vice President and Former Chief Financial Officer Chris Prentiss - ...
1Q 2024 Total revenues of $66M; +63% vs. 1Q 2023 1Q 2024 Net income of $11M; Non-GAAP net income of $15M $304M of cash and cash equivalents and investments at March 31, 2024 In early April, repaid Midcap senior-secured debt and Mann Group convertible debt totaling a...
Apartment Investment and Management Company (AIV) is expected to report for Q1 2024 Shopify Inc. Class A Subordinate (SHOP) is expected to report $0.08 for Q1 2024 Beyond Meat Inc. (BYND) is expected to report $-0.68 for Q1 2024 Instructure Holdings Inc. (INST) is expected to report $...
2024-05-07 17:35:59 ET Major earnings expected after the bell on Wednesday include: Energy Transfer LP ( ET ) Airbnb ( ABNB ) The Trade Desk ( TTD ) AMC Entertainment Holdings ( AMC ) Innovative Industrial Properties ( IIPR ) Read the full a...
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., May 06, 2024 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) , a company focused on the development and commercialization of innovative inhaled therapeutic products and devices for patients with endocrine and orphan lung diseases, announced...
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., May 01, 2024 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) will release its 2024 first quarter financial results and its management will host a conference call to discuss the financial results and corporate updates at 5:00 PM (Eastern Tim...
News, Short Squeeze, Breakout and More Instantly...
Pulmatrix Announces Cross License Agreement and Transfer of Laboratory to MannKind Corporation PR Newswire Cross license involves Pulmatrix iSPERSE™ technology and MannKind's Cricket ® inhalation device. Pulmatrix transferring leased building,...
Immediate opportunity to increase capacity for formulation and early asset development in upgraded Boston area R&D space Non-cash deal includes royalty-free iSPERSE ™ technology license in exchange for access to MannKind’s Cricket ® inhaler ...
2024-05-09 00:15:12 ET Image source: The Motley Fool. MannKind (NASDAQ: MNKD) Q1 2024 Earnings Call May 08, 2024 , 5:00 p.m. ET Operator Continue reading For further details see: MannKind (MNKD) Q1 2024 Earnings Call Transcript